Eli Lilly and Co.

Financial pressures stretching Lilly

October 7, 2013
J.K. Wall
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
More

Lilly, other drugmakers itching to find new psoriasis treatment

October 4, 2013
Bloomberg News
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
More

Lilly to buy back $5B as sales goal harder to reach

October 3, 2013
Bloomberg News, J.K. Wall
Eli Lilly and Co. said Thursday that meeting its sale target will be a challenge. It plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate through patent losses. Another immediate hurdle: Obamacare.
More

Lilly shares dip after cancer treatment misses goal

September 26, 2013
Associated Press
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
More

Lilly bets quality over quantity will pay off in diabetes battle

September 24, 2013
Bloomberg News
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
More

Alzheimer’s targeted in $45M government study grant

September 18, 2013
Bloomberg News
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer's.
More

Drugmakers turn up marketing efforts in diabetes market

September 10, 2013
Bloomberg News
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
More

China bribery probe leading to tough drug market, CEO says

August 30, 2013
Bloomberg News
Drugmakers under investigation for bribery have stopped promoting products in China, and physicians in some hospitals no longer want to meet sales representatives. Eli Lilly is among the drugmakers in China facing allegations.
More

Lilly cites 'deep concerns' over China kickback allegations

August 22, 2013
Bloomberg News, Associated Press
Eli Lilly and Co. said it is investigating allegations its employees paid Chinese doctors at least $4.9 million in bribes and kickbacks to promote the sales of two diabetes drugs.
More

Lilly lung cancer drug raises patient survival in trial

August 13, 2013
Bloomberg News
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
More

Lilly's new strategy built around head-to-head drug trialsRestricted Content

August 10, 2013
J.K. Wall
Lilly has set up not one, not two, but five head-to-head trials of its experimental drug dulaglutide against other leading diabetes therapies. So far, dulaglutide’s record is four wins, no losses.
More

PROXY CORNER: Eli Lilly and Co.Restricted Content

August 3, 2013
Indianapolis-based Eli Lilly and Co. discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
More

Lilly shares rise after drugmaker reports solid second quarter

July 24, 2013
Bloomberg News, J.K. Wall
Strong sales and penny-pinching helped Eli Lilly and Co. beat Wall Street’s expectations in the second quarter, leading the company to raise its profit forecast for the year.
More

Lilly freezes pay for workers, executives

July 17, 2013
Bloomberg News
The pay freeze will save $400 million through 2016, said a spokesman for the Indianapolis-based company. Lilly won't give pay raises to executives, supervisors or most employees. Some bonuses will also be reduced.
More

Lilly aims potential Alzheimer’s drug at early patients

July 12, 2013
Bloomberg News
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
More

Lilly drug for Alzheimer's gets limited Medicare coverage

July 8, 2013
Bloomberg News, Associated Press
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
More

Lilly's Lechleiter back at helm after health scare

July 8, 2013
Associated Press
Eli Lilly and Co. Chairman and CEO John Lechleiter is back to full-time work after taking a leave in May to have surgery for a dilated aorta, the company announced Monday morning.
More

Miami man pleads guilty to $90M Lilly drug heist

July 1, 2013
Associated Press
Thieves broke into the Connecticut warehouse of Indianapolis-based Eli Lilly and Co. in 2010 by scaling an exterior wall and cutting a hole in the roof. They lowered themselves to the floor and disabled alarms before using a forklift to load pallets of drugs into a getaway vehicle.
More

Feds mull covering Alzheimer's test that uses Lilly's Amyvid

July 1, 2013
Bloomberg News
The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.
More

Lilly’s experimental diabetes drug helps patients lose weight

June 24, 2013
Bloomberg News
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
More

Lilly’s Zyprexa injection probed by FDA after deaths

June 18, 2013
Bloomberg News
Eli Lilly and Co.’s injectable form of the antipsychotic Zyprexa is being investigated by U.S. regulators after two patients died three to four days after receiving the drug.
More

Drugmakers may face ‘pay for delay’ suits, high court rules

June 18, 2013
Bloomberg News
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
More

Lilly to take over development of diabetes drug

June 17, 2013
Associated Press
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
More

Most of Indiana's largest public companies enjoyed strong 2012Restricted Content

June 15, 2013
Angie's List turned a profit for the first time in nearly two decades.
More

Lilly halts trial of experimental Alzheimers drug

June 14, 2013
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT